The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety
Open accessAbstract
Melatonin is extensively used in the USA in a non-regulated manner for sleep disorders. Prolonged release melatonin (PRM) is licensed in Europe and other countries for the short term treatment of primary insomnia in patients aged 55 years and over. However, a clear definition of the target patient population and well-controlled studies of long-term efficacy and safety are lacking. It is known that melatonin production declines with age. Some young insomnia patients also may have low melatonin levels. The study investigated whether older age or low melatonin excretion is a better predictor of response to PRM, whether the efficacy observed in short-term studies is sustained during continued treatment and the long term safety of such treatment. Adult outpatients (791, aged 18-80 years) with primary insomnia, were treated with placebo (2 weeks) and then randomized, double-blind to 3 weeks with PRM or placebo nightly. PRM patients continued whereas placebo completers were re-randomized 1:1 to PRM or placebo for 26 weeks with 2 weeks of single-blind placebo run-out. Main outcome measures were sleep latency derived from a sleep diary, Pittsburgh Sleep Quality Index (PSQI), Quality of Life (World Health Organzaton-5) Clinical Global Impression of Improvement (CGI-I) and adverse effects and vital signs recorded at each visit. On the primary efficacy variable, sleep latency, the effects of PRM (3 weeks) in patients with low endogenous melatonin (6-sulphatoxymelatonin [6-SMT] ≤8 μg/night) regardless of age did not differ from the placebo, whereas PRM significantly reduced sleep latency compared to the placebo in elderly patients regardless of melatonin levels (-19.1 versus -1.7 min; P = 0.002). The effects on sleep latency and additional sleep and daytime parameters that improved with PRM were maintained or enhanced over the 6-month period with no signs of tolerance. Most adverse events were mild in severity with no clinically relevant differences between PRM and placebo for any safety outcome. The results demonstrate short- and long-term efficacy and safety of PRM in elderly insomnia patients. Low melatonin production regardless of age is not useful in predicting responses to melatonin therapy in insomnia. The age cut-off for response warrants further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
Brzezinski, A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701163360306 · Cited by 1,549
Recommendations for a standard research assessment of insomnia
Buysse, D. J., Ancoli-Israel, S., Edinger, J. D., Lichstein, K. L., & Morin, C. M. (2006) · Sleep · doi:10.1093/sleep/29.9.1155 · Cited by 1,206
Bech, P., Olsen, L. R., Kjoller, M., & Rasmussen, N. K. (2003) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.145 · Cited by 1,015 · cited 1×
“PSQI [29,30] global score, component scores, and questions 2 and 4 filled in by the investigator with the patient; sleep diary (National Sleep Foundation diary) parameters (daytime and night-time) were filled in by patient each day in the morning in the 7 days preceding each visit; World Health Organization (WHO)-5 We…”
MethodRole of Melatonin in the Regulation of Human Circadian Rhythms and Sleep
Cajochen, C., Kräuchi, K., & Wirz‐Justice, A. (2003) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.2003.00989.x · Cited by 735 · cited 1×
“Melatonin promotes sleep in humans [4,5], presumably by inhibiting circadian wakefulness mechanisms [6,7] and affects the activity of brain networks compatible with sleep induction [8,9].”
BackgroundAssociation of sleep-wake habits in older people with changes in output of circadian pacemaker
Czeisler, C. A., Dumont, M., Duffy, J. F., Steinberg, J. D., Richardson, G. S., Brown, E. N., Sánchez, R., Ríos, C. D., & Ronda, J. M. (1992) · The Lancet · doi:10.1016/0140-6736(92)92817-y · Cited by 437
Practice Parameters for Using Polysomnography to Evaluate Insomnia: An Update
Littner, M., Hirshkowitz, M., Kramer, M., Kapen, S., Anderson, W. M., Bailey, D., Berry, R. B., Davila, D., Johnson, S., Kushida, C., et al. (2003) · Sleep · doi:10.1093/sleep/26.6.754 · Cited by 306
Circadian rhythms of melatonin and cortisol in aging
Sharma, M., Palacios-Bois, J., Schwartz, G., Iskandar, H., Thakur, M., Quirion, R., & Nair, N. P. V. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90178-9 · Cited by 260
Hofman, M. A., & Swaab, D. F. (1994) · Brain Research · doi:10.1016/0006-8993(94)90689-0 · Cited by 215
The benzodiazepine withdrawal symptom questionnaire
Tyrer, P., Murphy, S., & Riley, P. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90009-w · Cited by 188
Cited by
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
Circadian rhythm as a therapeutic target
Ruan, W., Yuan, X., & Eltzschig, H. K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00109-w · Cited by 486
Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders
Auld, F., Maschauer, E. L., Morrison, I., Skene, D. J., & Riha, R. L. (2017) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2016.06.005 · Cited by 393
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
Wilt, T. J., MacDonald, R., Brasure, M., Olson, C. M., Carlyle, M., Fuchs, E., Khawaja, I. S., Diem, S., Koffel, E., Ouellette, J., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1781 · Cited by 275
Metadata
- Authors
- Wade, A. G., Ford, I., Crawford, G., McConnachie, A., Nir, T., Laudon, M., & Zisapel, N.
- Venue
- BMC Medicine
- Published
- 2010-08-16
- Volume
- 8
- Issue
- 1
- Pages
- 51-51
- ISSN
- 1741-7015 (ISSN-L)
- OpenAlex
- W2088279489
- Cited by
- 178
- References
- 10
- FWCI
- 13.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. https://app.cochat.ai/papers/10.1186/1741-7015-8-51
- The paper
- Wade, A. G., Ford, I., Crawford, G., McConnachie, A., Nir, T., Laudon, M., & Zisapel, N. (2010). Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Medicine. https://doi.org/10.1186/1741-7015-8-51
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.